Rare Disease Peptides

Rare disease peptides address conditions affecting small patient populations, often with no alternative treatments available. Many of these compounds have received FDA Orphan Drug Designation, which provides regulatory and commercial incentives for development. Despite targeting niche indications, these peptides represent some of the most scientifically innovative and clinically impactful peptide therapeutics.

Vosoritide is a modified C-type natriuretic peptide analog approved for achondroplasia, the most common form of short-limbed dwarfism, representing the first drug to directly address the underlying pathophysiology of this skeletal dysplasia. Setmelanotide is an MC4R agonist approved for severe obesity caused by specific genetic deficiencies in the leptin-melanocortin pathway, including POMC, PCSK1, and LEPR deficiency. Afamelanotide, an alpha-MSH analog, is approved for erythropoietic protoporphyria (EPP), a rare photosensitivity disorder. Enfuvirtide, an HIV fusion inhibitor, was developed for treatment-experienced HIV patients with multidrug-resistant virus. Plerixafor, a CXCR4 antagonist, is approved for stem cell mobilization in patients who are poor mobilizers.

All peptides in this category have undergone rigorous clinical development and received regulatory approval for their respective indications.